Stock BRM BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Insiders Bristol-Myers Squibb Company Xetra

Equities

BRM

US1101221083

Real-time Estimate Tradegate
Other stock markets
 08:02:12 2024-07-16 am EDT 		5-day change 1st Jan Change
36.88 EUR +0.18% Intraday chart for Bristol-Myers Squibb Company -0.82% -20.36%
Jul. 15 Transcript : Bristol-Myers Squibb Company Presents at UBS Virtual Targeted Protein Degradation Day, Jul-15-2024 11:00 AM
Jul. 12 UBS Cuts Bristol-Myers Squibb Price Target to $43 From $47, Maintains Neutral Rating MT

Insiders

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Cartesian Therapeutics, Inc. Appoints Kemal Malik to its Board of Directors
CI
Bristol Myers: ex-CEO of Agilent joins Board of Directors
CF
Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024
CI
Germany's Evotec appoints Christian Wojczewski as CEO
RE
Novartis Nominates Former Bristol Myers Squibb CEO as New Chair
MT
Novartis Lifts 2024 Guidance as First-quarter Earnings Grow on Strong Blockbuster Drug Demand
MT
Bristol-Myers Squibb Company Announces Gerald Storch Not to Stand for Re-Election to the Board
CI
Arvinas Appoints Noah Berkowitz as Chief Medical Officer
MT
Aurora Cannabis Names Simona King CFO; Completes Share Consolidation
MT
Bristol-Myers Squibb Company Announces Management Changes
CI
Lonza chairman to step down, drugmaker confirms targets, shares soar
RE
Evotec says it promptly reported share trades withheld by former CEO
RE
Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology
MT
Avacta taps biopharma veteran as Therapeutics business chief
AN
UniCredit seeks new chair candidate by early 2024, sources say
RE
UniCredit seeks new presidential candidate by early 2024 - sources
RE
UniCredit seeks new chair candidate by early 2024, sources say
RE
Bristol Myers Squibb Insider Bought Shares Worth $150,049, According to a Recent SEC Filing
MT
Bristol Myers Squibb Insider Bought Shares Worth $423,385, According to a Recent SEC Filing
MT
Bristol-Myers Squibb Names Christopher Boerner as Chair
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BMY Stock
  4. BRM Stock
  5. News Bristol-Myers Squibb Company
  6. Insiders